Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience

Table 4 Treatment and survival of the 13 patients with IgD subtype MM

Patient no.	ISS stage	Sex	Age (years)	Introduction therapy/cycles	Response	Therapy after PD/cycles	Survival status	PFS (months)	OS (months)
1	III	Male	51	CTD/5	CR	RAD/6	Alive	6.0	17.6
2	III	Female	53	CTD/7	PR	RD/8	Alive	8.0	19.5
3	III	Male	64	VCD/1	PD	NA	Dead	0.7	0.9
4	III	Male	48	VTD/8	PR	RCD	Dead	26.2	44.3
5	III	Female	59	VTD/2	SD	NA	Dead	5.1	5.7
6	III	Male	44	VCD/9	CR	TAD/6 + RAD/6	Alive	42.3	47.0
7	III	Female	49	VTD/9	CR	RAD/10	Dead	28.0	42.6
8	III	Male	52	VCD/9	VGPR	RD/6	Dead	8.5	13.0
9	III	Male	45	VCD/2	CR	CTD/8	Alive	2.4	9.2
10	III	Male	59	VD/4	PR	VCTD/5	Dead	16.7	16.7
11	III	Male	51	CTD/5	PR	RAD/3	Dead	10.0	6.6
12	III	Female	56	VCD/4 + ASCT	VGPR	CTD/4	Dead	18.7	22.9
13	III	Female	66	VD/4	VGPR	RD/6	Dead	48.0	66.0

IgD immunoglobulin D, ISS international staging system, PD progressive disease, PFS progression-free survival, OS overall survival, CTD thalidomide + cyclophosphamide + dexamethasone, CR complete response, RAD lenalidomide + adriamycin + dexamethasone, PR partial response, RD lenalidomide + dexamethasone, VCD bortezomib + cyclophosphamide + dexamethasone, PD progressive disease, NA not applicable, VTD bortezomib + thalidomide + dexamethasone, RCD lenalidomide + cyclophosphamide + dexamethasone, SD stable disease, TAD thalidomide + adriamycin + dexamethasone, VGPR very good partial response, VD bortezomib + dexamethasone, VCTD bortezomib + thalidomide + cyclophosphamide + dexamethasone, ASCT autologous stem cell transplantation

ISSN: 2523-3548